This study compares the safety and effectiveness of continuing your current anti-HIV
medications to that of adding or switching some of your anti-HIV medications. It will follow
the effect of these medication changes, including the addition of hydroxyurea (HU), on
long-term viral suppression. Other medications which may be added include didanosine (ddI)
and/or stavudine (d4T).
Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine
(ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more.
Discontinuation of one or two of these drugs results in prompt loss of the viral
suppression. Other studies show that addition of HU to some reverse transcriptase inhibitor
treatments results in increased antiviral effects. This study will provide further
information on the effect of adding HU to a treatment regimen with respect to long-term
viral suppression.
Minimum age: 13 Years.
Maximum age: N/A.
Gender(s): Both.
Alabama Therapeutics CRS, Birmingham, Alabama 35294, United States
Stanford CRS, Palo Alto, California 943055107, United States
Ucsd, Avrc Crs, San Diego, California 921036325, United States
San Mateo County AIDS Program, San Mateo, California 943055107, United States
Harbor-UCLA Med. Ctr. CRS, Torrance, California 90502, United States
University of Colorado Hospital CRS, Aurora, Colorado 80262, United States
Univ. of Miami AIDS CRS, Miami, Florida 331361013, United States
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii 96816, United States
Northwestern University CRS, Chicago, Illinois 60611, United States
Weiss Memorial Hosp., Chicago, Illinois 60640, United States
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana 46202, United States
Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis, Indiana 462025250, United States
Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City, Iowa 52242, United States
Tulane Hemophilia Treatment Ctr., New Orleans, Louisiana 70112, United States
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland 21287, United States
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts 02215, United States
Massachusetts General Hospital ACTG CRS, Boston, Massachusetts 02114, United States
University of Minnesota, ACTU, Minneapolis, Minnesota 55455, United States
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri 63112, United States
Washington U CRS, St. Louis, Missouri, United States
Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr., Omaha, Nebraska 681985130, United States
Beth Israel Med. Ctr. (Mt. Sinai), New York, New York 10003, United States
Beth Israel Med. Ctr., ACTU, New York, New York, United States
NY Univ. HIV/AIDS CRS, New York, New York 10016, United States
Univ. of Rochester ACTG CRS, Rochester, New York 14642, United States
Unc Aids Crs, Chapel Hill, North Carolina 275997215, United States
Carolinas HealthCare System, Carolinas Med. Ctr., Charlotte, North Carolina 28203, United States
Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina 27401, United States
Univ. of Cincinnati CRS, Cincinnati, Ohio 452670405, United States
Case CRS, Cleveland, Ohio 44106, United States
MetroHealth CRS, Cleveland, Ohio 441091998, United States
The Ohio State Univ. AIDS CRS, Columbus, Ohio 432101228, United States
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania 19104, United States
University of Washington AIDS CRS, Seattle, Washington 98104, United States
Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD; ACTG 5025 Study Group. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS. 2001 Jul 27;15(11):1379-88.